Free Trial
NASDAQ:BPMC

Blueprint Medicines (BPMC) Stock Price, News & Analysis

Blueprint Medicines logo
$83.41 -0.77 (-0.91%)
Closing price 04/22/2025 04:00 PM Eastern
Extended Trading
$83.34 -0.06 (-0.08%)
As of 04/22/2025 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Blueprint Medicines Stock (NASDAQ:BPMC)

Key Stats

Today's Range
$83.27
$85.41
50-Day Range
$79.22
$96.57
52-Week Range
$73.04
$121.90
Volume
919,766 shs
Average Volume
769,800 shs
Market Capitalization
$5.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$124.95
Consensus Rating
Moderate Buy

Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

BPMC MarketRank™: 

Blueprint Medicines scored higher than 49% of companies evaluated by MarketBeat, and ranked 496th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Blueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 15 buy ratings, 6 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Blueprint Medicines has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Blueprint Medicines' stock forecast and price target.
  • Earnings Growth

    Earnings for Blueprint Medicines are expected to grow in the coming year, from ($1.28) to $0.65 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Blueprint Medicines is -77.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Blueprint Medicines is -77.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Blueprint Medicines has a P/B Ratio of 17.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Blueprint Medicines' valuation and earnings.
  • Percentage of Shares Shorted

    8.82% of the float of Blueprint Medicines has been sold short.
  • Short Interest Ratio / Days to Cover

    Blueprint Medicines has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Blueprint Medicines has recently increased by 7.57%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Blueprint Medicines does not currently pay a dividend.

  • Dividend Growth

    Blueprint Medicines does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.82% of the float of Blueprint Medicines has been sold short.
  • Short Interest Ratio / Days to Cover

    Blueprint Medicines has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Blueprint Medicines has recently increased by 7.57%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Blueprint Medicines has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Blueprint Medicines this week, compared to 7 articles on an average week.
  • Search Interest

    Only 2 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Blueprint Medicines to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $512,737.00 in company stock.

  • Percentage Held by Insiders

    Only 4.21% of the stock of Blueprint Medicines is held by insiders.

  • Read more about Blueprint Medicines' insider trading history.
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Stock News Headlines

Wedbush Reduces Earnings Estimates for Blueprint Medicines
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Q3 Earnings Forecast for BPMC Issued By Wedbush
Blueprint Medicines (BPMC) Receives a Buy from Wedbush
See More Headlines

BPMC Stock Analysis - Frequently Asked Questions

Blueprint Medicines' stock was trading at $87.22 at the start of the year. Since then, BPMC stock has decreased by 4.4% and is now trading at $83.41.
View the best growth stocks for 2025 here
.

Blueprint Medicines Co. (NASDAQ:BPMC) released its quarterly earnings results on Thursday, February, 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.11. Blueprint Medicines had a negative trailing twelve-month return on equity of 77.49% and a negative net margin of 13.19%.
Read the conference call transcript
.

Blueprint Medicines (BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines' top institutional investors include Rhumbline Advisers (0.14%), Assenagon Asset Management S.A. (0.12%), GAMMA Investing LLC (0.05%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Jeffrey W Albers, Kate Haviland, Christina Rossi, Fouad Namouni, Tracey L Mccain, Michael Landsittel, Debra Durso-Bumpus, Percy H Carter, Christopher K Murray, Philina Lee, L Becker Hewes and Ariel Hurley.
View institutional ownership trends
.

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
2/20/2025
Today
4/22/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BPMC
Fax
N/A
Employees
640
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$124.95
High Stock Price Target
$168.00
Low Stock Price Target
$76.00
Potential Upside/Downside
+49.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
23 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-67,090,000.00
Pretax Margin
-12.94%

Debt

Sales & Book Value

Annual Sales
$508.82 million
Price / Cash Flow
N/A
Book Value
$4.67 per share
Price / Book
17.86

Miscellaneous

Free Float
61,216,000
Market Cap
$5.33 billion
Optionable
Optionable
Beta
0.75

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:BPMC) was last updated on 4/23/2025 by MarketBeat.com Staff
From Our Partners